Why the study?
Does reperfusion therapy reduce mortality in patients with acute myocardial infarction?
Does reperfusion therapy reduce mortality in patients with acute myocardial infarction?
This historical review highlights the evolution and substantial mortality benefit of reperfusion therapy for acute myocardial infarction.
Answers are grounded in this paper and cite their sources.
Reperfusion remains foundational in AMI; confirms early megatrials while leaving optimization questions open for research.
Reperfusion therapy for acute myocardial infarction is a milestone achievement in 20th century cardiology. This article tracks this therapy from the discovery that coronary thrombosis is the cause of myocardial infarction, through the pre-clinical era when studies in dogs demonstrated the benefit of early reperfusion. Then came early clinical observations in the feasibility of coronary thrombolysis in patients, followed by the early placebo-controlled megatrials (GISSI-I and ISIS-2), which showed a substantial mortality benefit. During the past decade there have been important refinements using ambulance-based therapy, new bolus thrombolytics, adjunctive glycoprotein inhibitors and percutaneous coronary intervention.
No takes yet. Share an insight, caveat, or question.
Eugene Braunwald (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: